<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468334</url>
  </required_header>
  <id_info>
    <org_study_id>RS-011, Appendix 16</org_study_id>
    <nct_id>NCT04468334</nct_id>
  </id_info>
  <brief_title>aMAZE Trial Continued Access Protocol</brief_title>
  <acronym>aMAZE CAP</acronym>
  <official_title>Non-randomized, Multicenter Expanded Use Evaluation of the LARIAT® Suture Delivery Device (Appendix 16 to Ongoing Investigation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtriCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtriCure, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      aMAZE CAP is an extension to the current aMAZE Trial investigation&#xD;
      (IDEG150107/NCT02517397/Protocol Appendix 16) in the form of a nested, non-randomized&#xD;
      registry, to allow ongoing treatment of subjects and the collection of additional safety and&#xD;
      effectiveness data at existing aMAZE investigational sites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For consistency, aMAZE CAP primary and secondary safety and efficacy endpoints, eligibility&#xD;
      criteria and follow up visit assessments remain unchanged from the current aMAZE Trial&#xD;
      investigation (NCT02517397).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from episodes of atrial fibrillation &gt; 30 seconds at 12 months post index pulmonary vein isolation</measure>
    <time_frame>12 months following Pulmonary Vein Isolation catheter ablation procedure</time_frame>
    <description>Measured by 24-hour Holter Monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from any atrial fibrillation/atrial tachycardia/atrial flutter recurrence defined as any episode &gt; 30 seconds with or without AAD</measure>
    <time_frame>Following the 90 day blanking period through 12 months post-index pulmonary vein isolation</time_frame>
    <description>Measured by 24-hour Holter Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of stroke of any cause and systemic embolism as adjudicated by the clinical events committee</measure>
    <time_frame>12 months following index pulmonary vein isolation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>LARIAT Technical Success</measure>
    <time_frame>Immediately post-LARIAT ligation (acute) and at 12 months following index pulmonary vein isolation</time_frame>
    <description>Successful placement of the LARIAT device pre-tied suture around the left atrial appendage to achieve left atrial appendage ligation defined as ≤1 ± 1mm diameter residual communication w/ left atrium, as assessed by transesophageal echocardiography</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>LARIAT + PVI Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation&#xD;
Subgroup 1: Radiofrequency (RF) PVI catheter ablation treatment (n&lt;65) Subgroup 2: Cryoballoon PVI catheter ablation treatment (n&lt;20)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LARIAT + PVI</intervention_name>
    <description>LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures</description>
    <arm_group_label>LARIAT + PVI Treatment Group</arm_group_label>
    <other_name>LAA + RF PVI</other_name>
    <other_name>LAA + Cryo PVI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of symptomatic continuous persistent or longstanding persistent&#xD;
             non-valvular atrial fibrillation&#xD;
&#xD;
          -  Failed at least one Class I or III Antiarrythmic drug (AAD) and therefore, eligible&#xD;
             and intended for standard of care catheter ablation;&#xD;
&#xD;
          -  Life expectancy ≥ 1 year;&#xD;
&#xD;
          -  Willing and able to return to and comply with scheduled follow-up visits and tests;&#xD;
             and&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior procedure involving opening of the pericardium or entering the pericardial space&#xD;
             (e.g., coronary artery bypass graft, heart transplantation, valve surgery) where&#xD;
             adhesions are suspected;&#xD;
&#xD;
          -  Any prior epicardial ablation or any type of left-sided atrial ablation procedure;&#xD;
&#xD;
          -  LA diameter &gt; 6 cm as measured by computerized tomography and confirmed by the imaging&#xD;
             core laboratory;&#xD;
&#xD;
          -  Documented embolic stroke, transient ischemic attach or suspected neurologic event&#xD;
             within 3 months prior to the planned study intervention;&#xD;
&#xD;
          -  Currently exhibits New York Heart Association Class IV heart failure symptoms;&#xD;
&#xD;
          -  Documented history of right heart failure specifically when right ventricle exceeds&#xD;
             the left ventricular size;&#xD;
&#xD;
          -  Documented history of myocardial infarction (MI) within 3 months prior to the planned&#xD;
             study intervention;&#xD;
&#xD;
          -  Documented history of unstable angina within 3 months prior to the planned study&#xD;
             intervention;&#xD;
&#xD;
          -  Documented history of cardiogenic shock, hemodynamic instability or any medical&#xD;
             condition in which intra-aortic balloon pump (IABP) therapy is clinically indicated&#xD;
             within 3 months prior to the planned study intervention;&#xD;
&#xD;
          -  Documented symptomatic carotid disease, defined as &gt; 70% stenosis or &gt; 50% stenosis&#xD;
             with symptoms;&#xD;
&#xD;
          -  Diagnosed active local or systemic infection, septicemia or fever of unknown origin at&#xD;
             tme of baseline screening;&#xD;
&#xD;
          -  Chronic renal insufficiency defined as eGFR &lt; 30 mL/min/1.73m2 within 3 months prior&#xD;
             to planned study intervention;&#xD;
&#xD;
          -  End Stage Renal Disease (ESRD) or documented history of renal replacement / dialysis;&#xD;
&#xD;
          -  Current documented history of clinically significant liver disease which predisposes&#xD;
             the subject to significant bleeding risk (clinically defined by the treating&#xD;
             physician);&#xD;
&#xD;
          -  Any history of thoracic radiation with the exception of localized radiation treatment&#xD;
             for breast cancer;&#xD;
&#xD;
          -  Current documented use of long-term treatment with oral corticoid steroids, not&#xD;
             including use of inhaled steroids for respiratory diseases;&#xD;
&#xD;
          -  Active pericarditis;&#xD;
&#xD;
          -  Active endocarditis;&#xD;
&#xD;
          -  Any documented history or autoimmune disease associated with pericarditis;&#xD;
&#xD;
          -  Evidence of Pectus Excavatum (documented and clinically defined by the treating&#xD;
             physician);&#xD;
&#xD;
          -  Untreated severe scoliosis (documented and clinically defined by treating physician);&#xD;
&#xD;
          -  Documented Left Ventricular Ejection Fraction (LVEF) &lt; 30% within 30 days prior to&#xD;
             planned intervention;&#xD;
&#xD;
          -  Documented presence of implanted congenital defect closure devices, (e.g., atrial&#xD;
             septal defect, patent foramen ovale or ventricular septal defect device);&#xD;
&#xD;
          -  Previously attempted occlusion of the left atrial appendage (by any surgical or&#xD;
             percutaneous method);&#xD;
&#xD;
          -  Inability, or unwillingness or contraindication to undergo TEE or CTA imaging or&#xD;
             24-hour Holter monitoring;&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 40;&#xD;
&#xD;
          -  Evidence of active Graves disease;&#xD;
&#xD;
          -  Current untreated hypothyroidism;&#xD;
&#xD;
          -  Any contraindication to suture, endovascular device, or other minimally invasive&#xD;
             techniques including percutaneous, transseptal, and/or sub-xiphoid access;&#xD;
&#xD;
          -  Subject is pregnant or plans / desires to get pregnant within next 12 months;&#xD;
&#xD;
          -  Current enrollment in an investigation or study of an investigational device or&#xD;
             investigational drug that would interfere with this study and the required follow up;&#xD;
&#xD;
          -  Mental impairment or other psychiatric conditions which may not allow patient to&#xD;
             understand the nature, significance and scope of the study;&#xD;
&#xD;
          -  Any other criteria, medical illness or comorbidity which would make the subject&#xD;
             unsuitable to participate in this study as determined by the clinical site Primary&#xD;
             Investigator;&#xD;
&#xD;
        Additional Exclusion Criteria: Based on Screening / Pre-procedure Imaging&#xD;
&#xD;
        Subjects will also be excluded if they meet any of the following:&#xD;
&#xD;
        Based on screening computed tomography angiography performed within 90 days prior to study&#xD;
        intervention as confirmed by the core lab:&#xD;
&#xD;
        Left atrial appendage morphology: Superior-posterior oriented left atrial appendage (i.e.&#xD;
        superior C shape), that has Left atrial appendage distal apex extending posterior to the&#xD;
        ostium of the appendage.&#xD;
&#xD;
        Left atrial appendage positioned behind the pulmonary artery; or All other left atrial&#xD;
        morphology: Left atrial appendage LARIAT approach width &gt; 50 mm.&#xD;
&#xD;
        Based on a peri-procedural imaging (transesophageal echocardiography) at time of LARIAT or&#xD;
        catheter ablation) and confirmed by institution's designated LARIAT echocardiographer:&#xD;
&#xD;
        Intracardiac thrombus; or Significant mitral valve stenosis (i.e., mitral valve stenosis &lt;&#xD;
        1.5cm2)&#xD;
&#xD;
        NOTE: It is anticipated that a majority of subjects enrolled in the aMAZE CAP Trial will be&#xD;
        elderly US Medicare beneficiaries. Therefore, the results from the aMAZE CAP Trial are&#xD;
        expected to be generalizable to the Medicare population&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Wilber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University Department of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dhanunjaya Lakkireddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kansas City Cardiac Arrhythmia Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Arrhythmia Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's HealthCare</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University / Bluhm Cardiovascular Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Center for Heart and Vascular Medicine</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Central DuPage Hospital</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cardiac Arrhythmia Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South Clinical Research Corporation</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UP Health System- Marquette</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <zip>49855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Oregon Cardiology</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Medical Specialists Association / Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trident Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor - St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christus Trinity Mother Frances Health System</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lee RJ, Lakkireddy D, Mittal S, Ellis C, Connor JT, Saville BR, Wilber D. Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): Rationale and design. Am Heart J. 2015 Dec;170(6):1184-94. doi: 10.1016/j.ahj.2015.09.019. Epub 2015 Oct 3.</citation>
    <PMID>26678640</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left Atrial Appendage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

